Validation of a Dermatology-Specific Treatment Satisfaction Instrument
Sponsor
University of Southern California (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05056168
Collaborator
Icahn School of Medicine at Mount Sinai (Other), Brigham and Women's Hospital (Other)
120
5.6
Study Details
Study Description
Brief Summary
The primary objective of this study is to validate a dermatology-specific questionnaire that assesses patient satisfaction with their treatments across various inflammatory dermatology diseases.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
120 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Validation of a Dermatology-Specific Treatment Satisfaction Instrument
Anticipated Study Start Date
:
Nov 13, 2021
Anticipated Primary Completion Date
:
Mar 1, 2022
Anticipated Study Completion Date
:
May 1, 2022
Outcome Measures
Primary Outcome Measures
- Validity and reliability of a dermatology-specific treatment satisfaction instrument in patients with psoriasis [8 months]
For this survey study, the investigators will gather descriptive statistics for each item in the questionnaire. The investigators will also measure the following psychometric properties: measurement error, reliability and construct validity, as measured by convergent and known-groups validity
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Adult (≥ 18 years)
-
Psoriasis patients undergoing some form of treatment
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- University of Southern California
- Icahn School of Medicine at Mount Sinai
- Brigham and Women's Hospital
Investigators
- Principal Investigator: April Armstrong, MD, MPH, University of Southern California
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
April Armstrong,
Professor,
University of Southern California
ClinicalTrials.gov Identifier:
NCT05056168
Other Study ID Numbers:
- HS-18-00891-AM004
First Posted:
Sep 24, 2021
Last Update Posted:
Oct 21, 2021
Last Verified:
Oct 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: